Literature DB >> 10990152

Hexarelin exhibits protective activity against cardiac ischaemia in hearts from growth hormone-deficient rats.

F Berti1, E Müller, V De Gennaro Colonna, G Rossoni.   

Abstract

Male rats were treated with growth hormone (GH)-releasing hormone antiserum to induce selective GH deficiency. The chronic administration of hexarelin to these GH-deficient rats had a pronounced protective effect against ischaemic and post-ischaemic ventricular dysfunction. Hexarelin prevented hyper-responsiveness of the coronary vascular bed to angiotensin II and also prevented the reduction in generation of 6-keto-prostaglandin F1alpha in perfused hearts from GH-deficient rats. The most plausible interpretation of these findings is that hexarelin acts via stimulation of specific cardiac and vascular receptors, triggering currently unknown cytoprotective mechanisms that are responsible for resistance to ischaemic insults and for the preservation of the integrity of the endothelial vasodilation function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10990152     DOI: 10.1016/s1096-6374(98)80041-5

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  11 in total

Review 1.  Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands: focus on reproductive system.

Authors:  E Arvat; L Gianotti; R Giordano; F Broglio; M Maccario; F Lanfranco; G Muccioli; M Papotti; A Graziani; E Ghigo; R Deghenghi
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 2.  Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases.

Authors:  Rasha Mofeed Habeeb Mosa; Zhen Zhang; Renfu Shao; Chao Deng; Jiezhong Chen; Chen Chen
Journal:  Endocrine       Date:  2015-02-04       Impact factor: 3.633

3.  [125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis.

Authors:  S D Katugampola; Z Pallikaros; A P Davenport
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

4.  Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans.

Authors:  G Bisi; V Podio; M R Valetto; F Broglio; G Bertuccio; G Del Rio; E Arvat; M F Boghen; R Deghenghi; G Muccioli; H Ong; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-04       Impact factor: 4.256

5.  Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice.

Authors:  Rasha Mosa; Lili Huang; Yeda Wu; Chungyan Fung; Oshini Mallawakankanamalage; Derek LeRoith; Chen Chen
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

6.  Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium.

Authors:  Yi Ma; Lin Zhang; Joshua N Edwards; Bradley S Launikonis; Chen Chen
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

Review 7.  Biologic activities of growth hormone secretagogues in humans.

Authors:  E Ghigo; E Arvat; R Giordano; F Broglio; L Gianotti; M Maccario; G Bisi; A Graziani; M Papotti; G Muccioli; R Deghenghi; F Camanni
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.925

Review 8.  The cardiovascular action of hexarelin.

Authors:  Yuanjie Mao; Takeshi Tokudome; Ichiro Kishimoto
Journal:  J Geriatr Cardiol       Date:  2014-09       Impact factor: 3.327

Review 9.  The CD36-PPARγ Pathway in Metabolic Disorders.

Authors:  Loïze Maréchal; Maximilien Laviolette; Amélie Rodrigue-Way; Baly Sow; Michèle Brochu; Véronique Caron; André Tremblay
Journal:  Int J Mol Sci       Date:  2018-05-21       Impact factor: 5.923

Review 10.  Growth Hormone Secretagogues and the Regulation of Calcium Signaling in Muscle.

Authors:  Elena Bresciani; Laura Rizzi; Silvia Coco; Laura Molteni; Ramona Meanti; Vittorio Locatelli; Antonio Torsello
Journal:  Int J Mol Sci       Date:  2019-09-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.